Latest news with #MounjaroKwikPen
Time Business News
7 days ago
- Health
- Time Business News
The Role of Sleep Quality in Mounjaro Weight Loss Outcomes: A UK Perspective
In recent years, the conversation around weight management in the UK has broadened beyond diet and exercise. Increasingly, factors such as emotional wellbeing, hormonal health, and sleep quality are being recognised as significant contributors to sustainable weight outcomes. This shift has coincided with the emergence of newer medications developed primarily for managing Type 2 Diabetes—one of the most prominent being Mounjaro (tirzepatide). While primarily indicated for blood glucose control, many individuals prescribed Mounjaro have observed notable weight loss benefits as a secondary outcome. However, to fully optimise these effects, supporting lifestyle factors like sleep quality should not be overlooked. This article explores how sleep interacts with the body's metabolic processes and how it may influence Mounjaro weight loss outcomes, particularly for those managing their health in the UK context. Mounjaro, the brand name for tirzepatide, is a once-weekly injectable medication prescribed for the management of Type 2 Diabetes. What sets Mounjaro apart from other medications is its dual action on two key gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones play a crucial role in regulating insulin secretion, appetite, and digestion. This dual receptor activity means the tirzepatide mechanism of action not only helps with glycaemic control but also reduces hunger and delays gastric emptying. These effects can contribute to modest weight loss, which has drawn attention from researchers and patients alike. Mounjaro is typically administered via the Mounjaro injection, and it is available in pen devices such as the MounjaroKwikPen, offering ease of use for patients prescribed the medication. Sleep is often seen as downtime, but metabolically, it is an active and essential process. Poor sleep quality or insufficient sleep disrupts hormonal balances that regulate hunger, insulin sensitivity, and stress. Specifically, sleep deprivation reduces leptin, the hormone responsible for satiety, while increasing ghrelin, which stimulates appetite. Moreover, lack of rest impairs insulin sensitivity, potentially leading to elevated blood glucose levels and increased fat storage. For individuals managing Type 2 Diabetes or trying to support their metabolism, sleep becomes an integral part of the equation. Given Mounjaro's role in blood sugar control and appetite regulation, there is growing interest in whether optimising sleep can enhance the medication's effectiveness, particularly in achieving sustained metabolic improvements. While clinical data directly linkingsleep quality and tirzepatide efficacy is still emerging, there is a strong biological rationale for synergy. The GLP-1 and GIP receptors targeted by Mounjaro are influenced by circadian rhythms—our body's internal clock. Poor sleep can disrupt these rhythms, potentially blunting hormonal responses. On the other hand, consistent and restorative sleep may allow these metabolic pathways to function optimally, thereby complementing the pharmacological effects of Mounjaro weight loss treatment. Moreover, fatigue from poor sleep may decrease physical activity levels or increase cravings for high-calorie foods, indirectly reducing the benefits seen from Mounjaro. Like all prescription medications, Mounjaro side effects vary from person to person. Some users report symptoms such as nausea, constipation, or fatigue, especially in the early stages of treatment. These effects, if persistent, could affect sleep quality. For example, gastrointestinal discomfort during the night may disrupt sleep cycles, and feelings of fatigue may mask deeper issues related to circadian misalignment. Patients are encouraged to report any persistent side effects to their healthcare provider, particularly if these are interfering with rest or daily functioning. In the UK, Mounjaro is approved for the treatment of Type 2 Diabetes, not explicitly for weight loss alone. It is available only by prescription and must be issued under the guidance of a qualified healthcare professional. Given the current MHRA regulations, medications like Mounjaro cannot be marketed directly for weight loss in the UK, even though weight reduction may be observed as a secondary effect. Patients interested in exploring whether Mounjaro for Type 2 Diabetes may be appropriate for their health situation should consult their GP or a specialist. Discussions should always be individualised, considering the full scope of metabolic health, including factors such as sleep. For those using Mounjaro as part of a diabetes management plan, here are a few practical strategies to enhance sleep: 1. Maintain a Regular Sleep Schedule Going to bed and waking up at the same time each day supports your circadian rhythm, which may also help stabilise hormone activity related to appetite and metabolism. 2. Limit Stimulants in the Evening Avoid caffeine, nicotine, or heavy meals close to bedtime. These can interfere with the quality of sleep and digestion—particularly important for individuals on medications affecting gastric emptying. 3. Mind the Timing of Mounjaro Injections Some patients find that the timing of the Mounjaro injection may influence when side effects like nausea or fatigue appear. Administering it at a time that allows side effects to resolve before sleep can be helpful. 4. Create a Sleep-Friendly Environment Cool temperatures, reduced light exposure, and a screen-free wind-down routine can all contribute to better sleep outcomes. 5. Stay Physically Active Regular, moderate exercise has been shown to improve sleep quality and enhance insulin sensitivity. It may also support the body's response to tirzepatide. When it comes to managing Type 2 Diabetes and supporting healthy weight outcomes, medications like Mounjaro offer a powerful tool. But pharmacological treatments rarely work in isolation. Lifestyle choices—especially adequate, high-quality sleep—can significantly influence the overall effectiveness of a treatment plan. By prioritising sleep hygiene alongside medication, physical activity, and nutrition, individuals may see more stable improvements in glucose regulation, appetite control, and body weight. As our understanding of the interplay between sleep and metabolic function continues to evolve, patients and healthcare providers alike should view rest not as a luxury, but as an essential part of therapeutic success. For patients who have been prescribed Mounjaro by a healthcare professional, Pharmacy Planet is a trusted UK-based online pharmacy offering regulated access to licensed treatments. You can buy Mounjaro, including the MounjaroKwikPen, through their platform following appropriate clinical assessment. They also provide additional information for those interested in buying tirzepatide compound under prescription. TIME BUSINESS NEWS
Time of India
26-06-2025
- Business
- Time of India
Eli Lilly to roll out diabetes medicine in prefilled pen
Eli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offers a convenient, once-weekly administration. It contains four fixed doses. This launch intensifies competition with Novo Nordisk's Wegovy. Mounjaro's dual mechanism may offer superior efficacy. The availability of all six dosage options will support personalized treatment. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads US pharmaceutical major Eli Lilly on Thursday announced its plan to launch blockbuster diabetes drug tirzepatide ) in KwikPen , a prefilled pen designed for once-a-week administration for single patients in the Indian market, two days after its rival Danish drug maker Novo Nordisk launched the weight loss drug Wegovy as a weekly injection in the country, intensifying competition in the booming obesity Lilly said it received the approval of the Indian drug regulatory authority but did not comment on the launch timeline. The expected price of the pen device was also not disclosed. Once launched, the company said each pen will deliver four fixed doses of 0.6 ml and has been approved in six dose strengths including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 launched earlier this week, is expected to be in the pharmacies by the end of this month. The delivery device will contain four doses of 0.25 mg, 0.5 mg and 1 mg priced at '17,345 a month. This translates into a weekly cost of '4,366. The 1.7 mg dose will be priced at '24,280 per month, and 2.4 mg dose will be priced at '26, Misra, chairman of Fortis C-DOC, Centre of Excellence for diabetes, metabolic diseases and endocrinology said Mounjaro's dual mechanism may offer superior efficacy, however "wider adoption" will depend on the "price" of the Tucker, president and general manager of Eli Lilly India, said the approval of Mounjaro KwikPen marks a step forward in the care of people living with type 2 diabetes and obesity, offering a convenient way for patients to take their medication. Mounjaro reduces body weight and decreases fat mass by regulating appetite."With this approval, all six dosage options for Mounjaro will soon be available in India, supporting a more personalised approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals," he is the first and only dual GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with one weight-related comorbidity.
Mint
26-06-2025
- Health
- Mint
Wegovy vs Mounjaro: Eli Lilly to launch full-dose pen device in India as obesity drug race heats up
Just months after introducing its weight-loss drug Mounjaro in India, US-based Eli Lilly is set to roll out a more convenient, pen-filled version—escalating its rivalry with Novo Nordisk in the country's nascent but high-potential obesity drug market. The US-based drugmaker announced on Thursday that it has received market authorization from the Central Drugs Standard Control Organisation (CDSCO) to launch the Mounjaro KwikPen, a multi-dose, single-patient-use prefilled pen designed for once-weekly administration. Until now, the drug was only available in injectable vials, in two dosage strengths. The full dosage range will soon be available in India, the company said. 'With this approval, all six dosage options for Mounjaro (tirzepatide) will soon be available in India, supporting a more personalized approach to treatment and allowing healthcare professionals to tailor care based on individual patient needs and clinical goals,' Winselow Tucker, president and general manager, Lilly India, said in the release. A pen-device is much easier for self-administration and preferred by patients over vials, according healthcare providers. While Eli Lilly gained an early mover advantage with Mounjaro's March 2025 launch, Novo Nordisk is counting on its pen-device format and insulin market leadership to help it close the gap, its India head Vikrant Shrotriya told Mint earlier this week. Eli Lilly's Mounjaro has sold over 81,570 units in India, with cumulative sales of ₹ 23.94 crore by May 2025, according to pharma intelligence platform Pharmarack. Novo Nordisk, which launched its rival drug Wegovy in India this week, has been losing global market share to Lilly in the anti-obesity space and entered the Indian market later. Both drugmakers face a narrow window to tap into India's largely unmet demand for chronic weight-loss medication—before generics arrive. Novo Nordisk is expected to lose patent protection on semaglutide, the active compound in Wegovy, by March 2026. Leading Indian pharmaceutical companies including Dr Reddy's, Sun Pharma, Zydus Lifesciences, and Cipla are reportedly preparing to launch lower-cost versions. Mounjaro is currently priced at ₹ 14,000 monthly for a 2.5 mg vial and ₹ 17,500 monthly for the 5 mg version. The company has not yet disclosed pricing for the remaining dosage options. Wegovy, also a once-weekly injectable, is being introduced in five dose levels: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The first three are priced at ₹ 4,336 per dose or ₹ 17,345 monthly, while the 1.7 mg dose is priced at ₹ 24,280 and the 2.4 mg at ₹ 26,015 per month. The growing competition between Lilly and Novo underscores the scale of the opportunity: India is home to more than 254 million people living with obesity and over 100 million adults with diabetes. The Indian weight loss market was estimated to be $25 billion in 2024, and could double in size by 2033, according to Nuvama research. With lifestyle-related illnesses rising and awareness around medical weight management slowly increasing, both companies are racing to establish a strong foothold before prices crash and the market fragments.
&w=3840&q=100)
Business Standard
26-06-2025
- Health
- Business Standard
India approves Eli Lilly's Mounjaro pen for diabetes, weight control
US pharma major Eli Lilly has now received approval from India's top drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its Mounjaro (tirzepatide) KwikPen format. Earlier in March, the company had launched Mounjaro in injectable vial form in 2.5 mg and 5 mg strengths. What is Mounjaro KwikPen and how does it work? According to Eli Lilly, the Mounjaro KwikPen is a multi-dose, single-patient-use, prefilled pen designed for once-weekly injections. It offers a more convenient way for people with type 2 diabetes and obesity to take their medication. Mounjaro is the first and only drug that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors—two hormones that help regulate blood sugar and appetite. In simple terms, Mounjaro helps: Improve insulin production Lower blood sugar levels Reduce body weight Control appetite All six dosage options of Mounjaro (2.5 mg to 15 mg) will soon be available in India. How does Mounjaro support weight management? The drug acts on hunger-regulating centres in the brain and slows stomach emptying, helping users feel full for longer. Clinical data show it improves fat metabolism and reduces body fat, contributing to weight loss. Who is eligible to use the Mounjaro KwikPen? The KwikPen is approved as an adjunct treatment with diet and exercise for: Adults with type 2 diabetes Adults with obesity (BMI ≥ 30) Overweight adults (BMI ≥ 27) with at least one weight-related condition such as high blood pressure or cholesterol When will Mounjaro KwikPen be available in India? While CDSCO has granted marketing authorisation, Lilly has not disclosed a launch date or pricing. The company has said this information will be announced soon. Mounjaro in vial form is priced at ₹3,500 (2.5 mg) and ₹4,375 (5 mg). Expert voices caution on long-term efficacy Speaking to Business Standard, Dr Ashish Gautam, Senior Director, Robotic and Laparoscopic Surgery at Max Super Speciality Hospital, said: 'The response towards anti-obesity medication in India has been positive, but the long-term benefits are yet to be established. While the medicines show good results during usage, weight tends to come back once medication is stopped.' He added that while drugs like Mounjaro are effective during use, bariatric surgery remains a more reliable long-term option for obesity. Sales surge and new competition from Wegovy According to PharmaTrac, Mounjaro has sold over 81,570 units in India as of May, with a 60 per cent rise in sales between April and May. On Tuesday, Danish drugmaker Novo Nordisk launched its blockbuster weight-loss drug Wegovy in India. It is expected to hit pharmacies by the end of the month, according to Novo Nordisk India MD Vikrant Shrotriya. India's obesity and diabetes burden continues to grow The National Family Health Survey (NFHS)-5 (2019–21) found that 24 per cent of women and 23 per cent of men aged 15–49 were overweight or obese, a sharp rise from 2015–16. The International Diabetes Federation projects that the number of adults with diabetes in India will grow from 74.2 million in 2021 to over 124 million by 2045.
New Indian Express
26-06-2025
- Health
- New Indian Express
India approves Eli Lilly's Mounjaro KwikPen for diabetes and obesity, offering a novel dual-action therapy
NEW DELHI: India's drug regulator has approved Eli Lilly and Company's diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant announced on Thursday. The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Mounjaro (tirzepatide) in the KwikPen format in India. According to the company, it is a multi-dose, prescription-based, single-patient-use prefilled pen designed for once-weekly administration. Each pen delivers four fixed doses of 0.6 mL and has been approved in six dosage strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. 'Mounjaro (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with one weight-related comorbidity,' the company said in a statement. The announcement comes just days after Novo Nordisk revealed the launch of its weight-loss product Wegovy, which is yet to be made available in India. 'The approval of Mounjaro KwikPen marks a step forward in the care of people living with type 2 diabetes and obesity, offering a convenient way for patients to take their medication,' said Winselow Tucker, President and General Manager, Lilly India.
